Rusch, Valerie

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 4,338

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Cited by 3,655

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 2,099

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,598

Characterizing the cancer genome in lung adenocarcinoma

Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 1,105

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics

Occupational and environmental lung diseasesChromatin Remodeling and Cancer

Cited by 717

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 646

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 643

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 605

Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.

Martin, J., Ginsberg, R. J., Venkatraman, E. S., Bains, M. S., Downey, R. J., Korst, R. J., Kris, M. G., & Rusch, V. W. (2002) · Journal of Clinical Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Cited by 195

High Telomerase Activity in Primary Lung Cancers: Association With Increased Cell Proliferation Rates and Advanced Pathologic Stage

Albanell, J., Engelhardt, M., Han, W., Moore, M. A. S., Lonardo, F., Rusch, V., Langenfeld, J., Klimstra, D., Venkatraman, E., & Dmitrovsky, E. (1997) · JNCI Journal of the National Cancer Institute

Telomeres, Telomerase, and SenescenceLung Cancer Research Studies

Cited by 193

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 146

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., et al. (2013) · Journal of Thoracic Oncology

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 122

Medical and Surgical Care of Patients with Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations

Carbone, M., Pass, H. I., Ak, G., Alexander, H. R., Baas, P., Baumann, F., Blakely, A. M., Bueno, R., Bzura, A., Cardillo, G., et al. (2022) · Journal of Thoracic Oncology

Occupational and environmental lung diseasesBRCA gene mutations in cancer

Cited by 97

New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center

Galateau Salle, F., Le Stang, N., Nicholson, A. G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V. L., Tazelaar, H. D., Vignaud, J. M., Attanoos, R., et al. (2018) · Journal of Thoracic Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 93

Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation

Chaft, J. E., Litvak, A., Arcila, M. E., Patel, P., D'Angelo, S. P., Krug, L. M., Rusch, V., Mattson, A., Coeshott, C., Park, B., et al. (2014) · Clinical Lung Cancer

Lung Cancer Treatments and MutationsImmunotherapy and Immune Responses

Cited by 78